CLINICAL TRIAL: SUBJECTS ON POTENT ANTIRETROVIRAL THERAPY WITH PLASMA HIV-1 RNA

临床试验：接受血浆 HIV-1 RNA 有效抗逆转录病毒治疗的受试者

• 批准号: 7717918
• 负责人: ANDREW RICHARD ZOLOPA
• 金额: $ 0.42万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717918
• 关键词: Bolus Infusion; CD4 Lymphocyte Count; CD4 Positive T Lymphocytes; Cell Count; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Daily; Dose; Double-Blind Method; Funding; Grant; Human; Institution; Phase; Placebos; Plasma; Randomized; Recombinants; Research; Research Design; Research Personnel; Resources; Source; United States National Institutes of Health; Upper arm; Viral Load result; antiretroviral therapy; day; keratinocyte growth factor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5212 is a double blind, phase II study designed to evaluate whether palifermin (recombinant human keratinocyte growth factor [rHuKGF]) is effective at increasing CD4+ lymphocyte counts through enhanced thymopoiesis in HIV-1-infected subjects with suppressed viral loads but inadequate CD4+ T cell counts. At entry, subjects will be randomized to one of four treatment arms to receive either placebo or one of three dose levels of palifermin intravenously (IV) bolus daily for 3 days.

这个子项目是众多研究子项目之一